Comparing Protalix BioTherapeutics (NYSE:PLX) & Invizyne Technologies (NASDAQ:IZTC)

Invizyne Technologies (NASDAQ:IZTC) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Analyst Ratings

This is a summary of recent ratings for Invizyne Technologies and Protalix BioTherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0	0	0	0	0.00
Protalix BioTherapeutics	0	0	1	0	3.00

Protalix BioTherapeutics has a consensus target price of $15.00, suggesting a potential upside of 549.35%. Given Protalix BioTherapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Invizyne Technologies.

Valuation and Earnings

This table compares Invizyne Technologies and Protalix BioTherapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Protalix BioTherapeutics	$61.95 million	2.97	$8.31 million	$0.07	33.00

Protalix BioTherapeutics has higher revenue and earnings than Invizyne Technologies.

Profitability

This table compares Invizyne Technologies and Protalix BioTherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Insider and Institutional Ownership

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 6.5% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Protalix BioTherapeutics beats Invizyne Technologies on 6 of the 9 factors compared between the two stocks.

About Invizyne Technologies

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.